Search the Newsreel

Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

This article highlights three companies that received new "Buy" ratings from Wall Street analysts. Lyell Immunopharma Inc., Immuneering Corp., and Atrium Therapeutics Inc. were initiated with bullish coverage, each receiving a price target significantly above their recent closing prices.

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc announced strong financial results for the second quarter and first half of 2026, driven by KIMMTRAK sales. The company reported $115.9 million in Q2 net revenues for KIMMTRAK, an 18% year-over-year increase, and highlighted positive five-year overall survival data for the …

Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock

Immunome (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the company's stock for approximately $2.27 million on August 4th, reducing their direct ownership by 64.27%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The clinical-stage biotechnology company, which focuses on antibody-based …

Zimmer Biomet (ZBH) Stock Gets Fair Value Bump After Mixed Analyst Views

Zimmer Biomet Holdings (ZBH) has seen its fair value updated by analysts, with some taking a bullish stance due to undervaluation and growth opportunities, while others remain cautious, emphasizing consistent execution and margin stabilization. The company's fair value moved from US$98.70 to approximately US$102.19, …

How First-Half Profitability Amid a Q2 Loss at Immunocore (IMCR) Has Changed Its Investment Story

Immunocore Holdings plc reported a significant Q2 2026 revenue increase to US$115.93 million and a narrower net loss, while the first half of 2026 saw US$222.60 million in revenue and US$12.16 million in net income, marking a shift to profitability compared to the prior …

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) following revelations about the company's former Chief Medical Officer, Richard Graydon, who was allegedly a fugitive named Ronald L. Fischer. Fischer had disappeared during a rape trial in …

ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake

ImmunityBio, Inc. (IBRX) is majority-controlled by Patrick Soon-Shiong and affiliated entities, who beneficially own 64.8% of the common stock, totaling 745,518,285 shares. This ownership is distributed among several entities, including Cambridge Equities, Nant Capital, California Capital Equity, and NantWorks. The report is based on …

Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year

Earnings Call Insights: Immunocore Holdings plc (IMCR) Q2 2026 MANAGEMENT VIEW * Dr. Bahija Jallal (CEO & Executive Director) emphasized execution against three priorities: "maximizing the value of KIMMTRAK, advancing our melanoma portfolio and expanding into other tumor types and realizing opportunities in infection …

IMNM (IMNM) investor ABHMC II LLC plans sale of 108,504 common shares

ABHMC II LLC, an investor in Immunome Inc. (IMNM), plans to sell 108,504 common shares via Merrill Lynch on or after August 6, 2026. These shares, valued at approximately $2.77 million, were acquired through a private placement on October 3, 2023. The filing also …

Immunovant, Inc. Q1 2027 Earnings Call Summary

Immunovant, Inc. Q1 2027 Earnings Call Summary - Moby Strategic Execution and Pipeline Acceleration Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Lyell Immunopharma: Q2 Earnings Snapshot

Calf-health company ImmuCell schedules Aug. 14 results webcast

ImmuCell (Nasdaq: ICCC) will report its unaudited financial results for the quarter ended June 30, 2026, after market close on August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results, …

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results. …

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to nine new employees on August 3, 2026. These options allow them to purchase an aggregate of 176,500 shares of common stock at an exercise price of $23.01 per share. …

Immunovant Q1 Earnings Call Highlights

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a "buy" rating and a $36.00 price target, suggesting a significant upside. This comes amidst generally favorable analyst sentiment, with an average "Moderate Buy" rating and a $42.00 target price from other firms. Lyell Immunopharma, …

Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary

Immunovant, Inc. reported a net loss of $153.2 million for Q1 2027, an increase from $120.6 million in the prior year, with diluted loss per share at $(0.75). The company generated no revenues for the quarter and is focusing on the development of IMVT-1402 …

Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...

Immunocore Holdings PLC reported strong Q2 2026 earnings, with Kimtrak generating $223 million in net revenue in the first half of 2026, marking a 16% year-over-year growth. The company presented positive five-year overall survival data for Kimtrak in uveal melanoma and is advancing three …

Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside

Immunovant, Inc.'s stock price target has been increased to $47.56 from $47.06 by 16 analysts, implying a 21% potential upside based on its Aug. 5 closing price. The consensus rating remains "Buy," with 12 analysts recommending Buy and 4 recommending Hold.

Zimmer Biomet Holdings, Inc. Stock 12‑Month Price Target Raised to $104.9, Implies 7% Upside

Zimmer Biomet Holdings, Inc.'s average price target has been increased to $104.9, up from $104.26, according to 20 analysts. This updated target suggests a potential 7% upside based on the Aug. 5 closing price. The consensus rating among 29 analysts remains a "Buy," with …

Immunocore Q2 2026 slides: KIMMTRAK doubles 5-year survival rates

Immunocore Holdings reported its Q2 2026 financial results, highlighting that its therapy KIMMTRAK doubled the five-year survival rates in metastatic uveal melanoma patients. The company reported $115.9 million in revenue, an 18% year-over-year growth, and narrowed its net loss significantly. Immunocore is expanding its …

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials …

JPMorgan Adjusts Price Target on Zimmer Biomet to $117 From $95

JPMorgan has raised its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $117 from $95. This adjustment was reported on August 6, 2026, at 12:02 pm EDT. The article also notes several other analyst adjustments for Zimmer Biomet on the same day.

UBS Adjusts Price Target on Zimmer Biomet to $120 From $115, Maintains Buy Rating

UBS has increased its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $120 from $115, while reaffirming a Buy rating on the stock. This adjustment comes amidst other analyst revisions for Zimmer Biomet on the same day, indicating active re-evaluation of the company's …

FMR LLC (IMCR) discloses 4.3M Immunocore shares under amended 13G

FMR LLC and Abigail P. Johnson have reported their beneficial ownership of Immunocore Holdings plc (IMCR) common stock via an amended Schedule 13G filing. FMR LLC beneficially owns 4,307,246 shares, representing an 8.8% stake, with sole dispositive power. Abigail P. Johnson also holds sole …

Zimmer Biomet sales force revamp going better than expected, CEO says

Zimmer Biomet's CEO Ivan Tornos announced that the company's transition to a fully dedicated sales force is progressing better than anticipated, leading to increased sales and earnings expectations for 2026. The restructuring, involving a shift of 2,500 U.S. sales personnel to dedicated specialists, has …

Deutsche Bank Adjusts Zimmer Biomet Price Target to $98 From $88, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $98, up from $88, while maintaining a "Hold" rating on the stock. This update reflects recent market activity and analyst assessments. The article also notes other analyst revisions for Zimmer …

AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit

AC Immune (NasdaqGM:ACIU) reported a surprise Q2 2026 profit with basic earnings per share of 0.018701 CHF and revenue of 15.113m CHF, a significant turnaround from a loss in the previous year. Despite this positive financial shift for the Alzheimer and neurodegeneration specialist, the …

Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026

Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with …

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36

Stifel has initiated coverage on Lyell Immunopharma, Inc. (LYEL.O) with a buy rating, setting a target price of $36. This announcement comes from Reuters and reflects an analyst's opinion on the company's prospects. The article also includes a disclaimer stating that the content is …

Immunocore (NASDAQ: IMCR) returns to profit as KIMMTRAK revenue climbs

Immunocore (NASDAQ: IMCR) reported a return to profit in the first half of 2026, driven by strong KIMMTRAK sales, with net revenue from therapies climbing to $222.6 million, a 16.0% increase year-over-year. The company posted a first-half net income of $12.2 million, a significant …

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant (Nasdaq: IMVT) announced its corporate updates and financial results for the first fiscal quarter ended June 30, 2026. The company's IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected for various trials between calendar years 2026 and 2028. …

Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch

Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient …

Shimmick Corporation $SHIM Stock Position Lowered by Sanders Morris Harris LLC

Regional Banks Stocks Q2 Results: Benchmarking First Interstate BancSystem (NASDAQ:FIBK)